
Horizon Tech Finance Pref Shares HTFB 4.875 03/30/26 | 8-K: FY2025 Q3 Revenue: USD 26.32 M

I'm PortAI, I can summarize articles.
Revenue: As of FY2025 Q3, the actual value is USD 26.32 M.
EPS: As of FY2025 Q3, the actual value is USD 0.68.
EBIT: As of FY2025 Q3, the actual value is USD -2.027 M.
Financial Metrics by Segment
Net Investment Income
- Net investment income (NII) for Q3 2025: $14.0 million, or $0.32 per basic share, compared to $11.8 million, or $0.32 per basic share for Q3 2024.
Total Investment Portfolio
- Total investment portfolio as of September 30, 2025: $603.5 million.
Net Asset Value
- Net asset value (NAV) as of September 30, 2025: $315.7 million, or $7.12 per share.
Portfolio Yield
- Annualized portfolio yield on debt investments for Q3 2025: 18.6%.
Loans and Investments
- Funded three loans totaling $15.0 million.
- Purchased remaining assets of a co-lender for $22.5 million, with a fair value of $36.5 million.
Capital Raising
- Raised total net proceeds of approximately $10.6 million through the ATM offering program.
Liquidity
- Cash as of September 30, 2025: $130.9 million.
- Credit facility capacity as of September 30, 2025: $329.0 million.
Undistributed Spillover Income
- Undistributed spillover income as of September 30, 2025: $0.93 per share.
Net Realized and Unrealized Gains/Losses
- Net realized loss on investments for Q3 2025: - $22.5 million, or - $0.52 per basic share.
- Net unrealized appreciation on investments for Q3 2025: $40.5 million, or $0.94 per basic share.
Operating Results
- Total investment income for Q3 2025: $26.3 million, compared to $24.6 million for Q3 2024.
- Total expenses for Q3 2025: $12.0 million, compared to $12.4 million for Q3 2024.
Cash Flow
- Cash of $130.9 million and credit facility capacity of $329.0 million as of September 30, 2025.
Outlook / Guidance
- Declared regular monthly distributions totaling $0.33 per share through March 2026.
- HRZN entered into an agreement for Monroe Capital Corporation to merge with and into HRZN, subject to shareholder approvals and other conditions.

